Dual-Action Incretin Drugs Outperform Single GLP-1 Drugs at Reducing Liver Fat and Fibrosis in Diabetics

This meta-analysis of 13 randomized controlled trials (1,552 patients) found that GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, and GCGR/GLP-1 receptor agonists all significantly reversed liver fibrosis (OR 3.72, p<0.001) and reduced liver fat content (mean decrease of 18.9%, p<0.001) in people with type 2 diabetes and fatty liver disease. Critically, dual-agonist drugs outperformed single GLP-1 agonists: GIP/GLP-1 agonists (like tirzepatide) showed an OR of 28.90 and GCGR/GLP-1 agonists an OR of 35.31 for liver fat reduction, compared to 8.23 for single GLP-1 agonists alone.

Systematic search of PubMed, Web of Science, Scopus, and Cochrane databases for randomized controlled trials examining GLP-1 agonists, dual GIP/GLP-1 agonists, or GCGR/GLP-1 agonists in patients with both type 2 diabetes and MASLD. Outcomes included liver fibrosis reversal and liver fat content measured by MRI. Random-effects meta-analysis calculated mean differences and odds ratios with 95% confidence intervals across 13 studies.

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects roughly 30% of the global population and is the fastest-growing cause of liver transplant. Until recently, there were no approved pharmacological treatments for liver fibrosis from fatty liver disease. This meta-analysis shows that incretin-based therapies — especially dual-agonist drugs — can both reduce liver fat and reverse fibrosis, potentially preventing progression to cirrhosis and liver failure. The superiority of dual agonists over single GLP-1 drugs is particularly significant for treatment selection.

Fatty liver disease has quietly become one of the world's most common chronic conditions, affecting nearly a third of the global population. The convergence of GLP-1-based obesity/diabetes drugs with liver disease treatment represents a potential game-changer — treating multiple metabolic conditions simultaneously. This meta-analysis adds to growing evidence that dual-agonist drugs (tirzepatide, survodutide) may be especially effective for liver disease, potentially establishing them as preferred treatments for the enormous population with overlapping diabetes and fatty liver disease.

The included studies likely had varying definitions of MASLD/fibrosis, different drug doses and durations, and heterogeneous patient populations. The comparison between dual and single agonists may be confounded by differences in study populations and follow-up periods. Most included trials were designed primarily for diabetes outcomes, with liver endpoints as secondary. The meta-analysis compares drug classes broadly rather than head-to-head comparisons of specific medications.